One Size Fits … Some [0.03%]
一步到位……适合某些人
Danielle Chammas
Danielle Chammas
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia [0.03%]
慢性淋巴细胞白血病未治疗患者固定疗程的Acalabrutinib联合治疗
Jennifer R Brown,John F Seymour,Wojciech Jurczak et al.
Jennifer R Brown et al.
Background: Whether fixed-duration acalabrutinib-venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (...
Richard S Finkel,Samuel H Hughes,JulieAnn Parker et al.
Richard S Finkel et al.
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply [0.03%]
低或超低HER2转移性乳腺癌中的曲妥珠单抗德鲁特卡ン。回应
Aditya Bardia,Maria Schwaederle,Giuseppe Curigliano
Aditya Bardia
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer [0.03%]
低水平或超低水平HER2转移性乳腺癌曲妥珠单抗德鲁替康治疗
Fabio Conforti,Chiara Oriecuia,Laura Pala
Fabio Conforti
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer [0.03%]
曲妥珠单抗德鲁替康在低表达或超低表达HER2的转移性乳腺癌中的应用
Riqing Huang,Meiting Chen,Yanxia Shi
Riqing Huang
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer [0.03%]
曲妥珠单抗德鲁特坎在低表达或超低表达HER2的转移性乳腺癌中的应用
Antonio C Wolff,Lisa M McShane,Kimberly H Allison
Antonio C Wolff
Paul M Ridker,Julie E Buring
Paul M Ridker
Chenlin Pei,Weishe Zhang,Jingrui Huang
Chenlin Pei
Chun Gui,Yuan Huang
Chun Gui